FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmacology, and represents a solid pharmaceutical composition containing: (a) a botulinum neurotoxin complex (type A, B, C, D, E, F or G) or high-purity botulinum neurotoxin (type A, B, C, D, E, F or G) in concentration 50 to 10000 units LD50 in 1 ml of solution, (b) a stabilising agent containing a surface-active substance in concentration from critical micelle formation concentration to 1 vol. % and not containing human serum albumin; (c) sodium chloride as a crystalline agent in concentration 0.1 to 0.5 M; (d) disaccharide in concentration 5 to 50 mM; (e) buffer for pH 5.5-7.5, or a liquid pharmaceutical composition additionally containing water.
EFFECT: invention provides stabilisation of the declared composition.
17 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIQUID COMPOSITION OF NEUROTOXIN STABILIZED WITH TRYPTOPHAN OR TYROSINE | 2017 |
|
RU2741497C2 |
| BOTULINUM TOXIN CONTAINING COMPOSITION | 2017 |
|
RU2743746C2 |
| PHARMACEUTICAL FORMULATION CONTAINING BOTULINUM NEUROTOXIN | 2013 |
|
RU2535115C1 |
| HIGH INTRODUCTION RATE OF NEUROTOXIC COMPONENT OF BOTULINUM TOXIN | 2007 |
|
RU2453333C2 |
| CLOSTRIDIAL NEUROTOXINS WITH MODIFIED PERSISTENCE | 2009 |
|
RU2524429C2 |
| SIMULTANEOUS, SEPARATE OR SEPARATED IN TIME THERAPEUTIC APPLICATION OF, AT LEAST, ONE BOTULIC NEUROTOXIN AND, AT LEAST, ONE OPIATE DERIVATIVE | 2007 |
|
RU2434637C2 |
| COMPLEX, AGENT AND APPLICATION OF TYPE A BOTULINUM TOXIN CLOSTRIDIUM BOTULINUM | 2020 |
|
RU2783511C1 |
| METHODS OF TREATING INCONTINENCE ASSOCIATED WITH SEXUAL ACTIVITY | 2012 |
|
RU2578475C2 |
| IMPROVED USE OF BOTULINUM NEUROTOXIN IN THE TREATMENT OF SIALORRHEA | 2018 |
|
RU2778481C2 |
| METHODS OF TREATING CHRONIC NEUROGENIC INFLAMMATION BY MODIFIED CLOSTRIDIAL TOXIN | 2010 |
|
RU2568844C2 |
